ZEALC Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Zealand Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 625.50 |
| 52 Week High | DKK 953.50 |
| 52 Week Low | DKK 588.50 |
| Beta | 0.53 |
| 1 Month Change | -15.62% |
| 3 Month Change | -16.88% |
| 1 Year Change | -8.92% |
| 3 Year Change | n/a |
| 5 Year Change | 250.22% |
| Change since IPO | 917.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZEALC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -2.7% |
| 1Y | -8.9% | -12.1% | 8.8% |
Return vs Industry: ZEALC exceeded the UK Biotechs industry which returned -11.5% over the past year.
Return vs Market: ZEALC underperformed the UK Market which returned 9.6% over the past year.
Price Volatility
| ZEALC volatility | |
|---|---|
| ZEALC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ZEALC's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ZEALC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 335 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
| ZEALC fundamental statistics | |
|---|---|
| Market cap | DKK 37.69b |
| Earnings (TTM) | -DKK 1.08b |
| Revenue (TTM) | DKK 62.69m |
601.2x
P/S Ratio-34.9x
P/E RatioIs ZEALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEALC income statement (TTM) | |
|---|---|
| Revenue | DKK 62.69m |
| Cost of Revenue | DKK 7.87m |
| Gross Profit | DKK 54.82m |
| Other Expenses | DKK 1.13b |
| Earnings | -DKK 1.08b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | -15.27 |
| Gross Margin | 87.44% |
| Net Profit Margin | -1,720.87% |
| Debt/Equity Ratio | 3.3% |
How did ZEALC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/10 06:19 |
| End of Day Share Price | 2025/03/03 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Hindley | Berenberg |
| Kerry Holford | Berenberg |
| Charlie Haywood | BofA Global Research |